FBRX

Forte Biosciences, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001419041

$17.56 +0.92% $359.6M

High Impact Filing (7/10)7 New Institutional Positions3 Institutional Exits

Vol

Market Cap$359.6M

Cap SizeSmall Cap

Inst. Holders38 funds

Inst. Value$212.4M

Inst. Activity7 buys / 3 sells

SEC Reports8

Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001419041·Prev Close $17.40

Recent Activity

Jun 11, 2026 SEC

Forte Biosciences' universal shelf registration (File No. 333-296425) became effective on June 10, 2026, enabling the co

EFFECT — Impact 6/10

Jun 8, 2026 SEC

Forte Biosciences filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $500M in securities (

S-3/A — Impact 6/10

Jun 5, 2026 SEC

Forte Biosciences filed a universal shelf registration statement on Form S-3 to offer and sell up to $500,000,000 in sec

S-3 — Impact 6/10

Jun 3, 2026 Event

Nalocet

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE AND ACETAMINOPHEN TABLETS Addictio

May 29, 2026 Insider

Brun Scott C. was granted 18,353 shares

Director

May 29, 2026 Insider

Kornfeld Steven was granted 18,353 shares

Director

May 29, 2026 Insider

GRYSKA DAVID W was granted 18,353 shares

Director

Inst.

ADAGE CAPITAL PARTNERS GP, — DOUBLED

950,000 shares ($24.6M)

Price Targets

Historical data — last covering-analyst action Nov 2025. No current recommendation available.

$63.75 (Nov 2025)

Current $17.56 Low $54.00 Median $63.00 High $75.00 4 analysts

$54.00 $75.00

Analyst Ratings

Historical distribution91% buy · 11 analysts · last covering-analyst action Nov 2025

3Strong Buy

7Buy

1Hold

0Sell

0Strong Sell

Historical Analyst Actions

Date	Firm	Action	Rating
Nov 25, 2025	Evercore ISI Group	INITIATE	Outperform
Nov 17, 2025	Chardan Capital	MAINTAIN	Buy → Buy
Aug 18, 2025	Guggenheim	INITIATE	Buy
Aug 15, 2025	Chardan Capital	MAINTAIN	Buy → Buy
Jun 24, 2025	Chardan Capital	MAINTAIN	Buy → Buy

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-1.01 ▲ +4.0%	$-1.11 — $-0.89	-5% YoY	4
Next Q	$-1.00 ▲ +3.4%	$-1.16 — $-0.90	-2% YoY	4
Current FY	$-4.01	$-4.67 — $-3.22	15% YoY	5
Next FY	$-4.14	$-5.36 — $-2.89	-3% YoY	5

Latest Reports

BEARISH EFFECT 6/10

Forte Biosciences' universal shelf registration (File No. 333-296425) became effective on June 10, 2026, enabling the co

Jun 11, 2026

BEARISH S-3/A 6/10

Forte Biosciences filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $500M in securities (

Jun 8, 2026

Top Institutional Holders

Fund	Value	Move
FEDERATED HERMES, INC.	$45.7M	ADD
FRED ALGER MANAGEMENT, LLC	$33.0M	ADD
JANUS HENDERSON GROUP PLC	$30.8M	ADD
ADAGE CAPITAL PARTNERS GP,	$24.6M	DOUBLED
VANGUARD CAPITAL MANAGEMENT LLC	$13.8M	—

Recent Insider Trades

Date	Insider	Type	Value
May 29, 2026	Brun Scott	A	$0.00
May 29, 2026	Kornfeld Steven	A	$0.00
May 29, 2026	GRYSKA DAVID	A	$0.00
May 29, 2026	VINCENT RICHARD	A	$0.00
May 29, 2026	Kapoor Shivpreet	A	$0.00

38 institutional holders with $212.4M total value (8,199,754 shares) as of 2026-Q1. Top holders: FEDERATED, FRED, JANUS. Net buying activity: 7 institutions added/increased vs 3 reduced.

Top Institutional Holders — 2026-Q1

#	Fund	Shares	Value	% of Tracked	Last Move
1	FEDERATED HERMES, INC.	1,765,516	$45.7M	21.5%	ADD +52.5%
2	FRED ALGER MANAGEMENT, LLC	1,273,965	$33.0M	15.5%	ADD +77.8%
3	JANUS HENDERSON GROUP PLC	1,188,060	$30.8M	14.5%	ADD +51.6%
4	ADAGE CAPITAL PARTNERS GP, L.L.C.	950,000	$24.6M	11.6%	DOUBLED +185.0%
5	VANGUARD CAPITAL MANAGEMENT LLC	531,692	$13.8M	6.5%	—
6	MORGAN STANLEY	500,298	$13.0M	6.1%	DOUBLED +609.3%
7	FMR LLC	340,695	$8.8M	4.2%	ADD +27.2%
8	Woodline Partners LP	331,987	$8.6M	4.0%	ADD +62.1%
9	CITADEL ADVISORS LLC	233,369	$6.0M	2.8%	—
10	MARSHALL WACE, LLP	150,307	$3.9M	1.8%	DOUBLED +314.1%
11	SUSQUEHANNA INTERNATIONAL GROUP, LLP	133,494	$3.5M	1.6%	—
12	AMERIPRISE FINANCIAL INC	111,788	$2.9M	1.4%	TRIM -26.9%
13	Russell Investments Group, Ltd.	91,772	$2.4M	1.1%	—
14	Trexquant Investment LP	73,651	$1.9M	0.9%	DOUBLED +470.2%
15	VANGUARD FIDUCIARY TRUST CO	72,095	$1.9M	0.9%	—
16	BlackRock, Inc.	65,921	$1.7M	0.8%	ADD +27.3%
17	STATE STREET CORP	54,821	$1.4M	0.7%	ADD +33.1%
18	GOLDMAN SACHS GROUP INC	53,473	$1.4M	0.7%	—
19	SUSQUEHANNA INTERNATIONAL GROUP, LLP	34,400	$891.0K	0.4%	—
20	WELLINGTON MANAGEMENT GROUP LLP	29,491	$763.8K	0.4%	—

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
ADAGE CAPITAL PARTNERS GP, L.L.C.	DOUBLED	333,333	950,000	+185.0%	$24.6M	2026-Q1
MORGAN STANLEY	DOUBLED	70,531	500,298	+609.3%	$13.0M	2026-Q1
MARSHALL WACE, LLP	DOUBLED	36,297	150,307	+314.1%	$3.9M	2026-Q1
AMERIPRISE FINANCIAL INC	TRIM	153,027	111,788	-26.9%	$2.9M	2026-Q1
Trexquant Investment LP	DOUBLED	12,916	73,651	+470.2%	$1.9M	2026-Q1
ENVESTNET ASSET MANAGEMENT INC	ADD	19,498	28,697	+47.2%	$743.3K	2026-Q1
BANK OF AMERICA CORP /DE/	DOUBLED	3,972	21,606	+444.0%	$559.6K	2026-Q1
Jain Global LLC	NEAR_EXIT	202,433	15,597	-92.3%	$404.0K	2026-Q1
NATIONAL BANK OF CANADA /FI/	DOUBLED	76	478	+528.9%	$12.4K	2026-Q1
Point72 Asset Management, L.P.	EXIT	487,275	0	-100.0%	$0.00	2026-Q1
Point72 Asset Management, L.P.	NEW	—	487,275	—	$13.3M	2025-Q4
FMR LLC	ADD	244,400	310,965	+27.2%	$8.5M	2025-Q4
AMERIPRISE FINANCIAL INC	DOUBLED	69,892	153,027	+118.9%	$4.2M	2025-Q4
MORGAN STANLEY	DOUBLED	151	70,531	+46609.3%	$1.9M	2025-Q4
BlackRock, Inc.	ADD	50,662	64,496	+27.3%	$1.8M	2025-Q4
STATE STREET CORP	ADD	38,097	50,721	+33.1%	$1.4M	2025-Q4
MARSHALL WACE, LLP	ADD	19,165	36,297	+89.4%	$989.8K	2025-Q4
BANK OF AMERICA CORP /DE/	ADD	3,158	3,972	+25.8%	$108.3K	2025-Q4
WELLS FARGO & COMPANY/MN	DOUBLED	2	502	+25000.0%	$13.7K	2025-Q4
GROUP ONE TRADING LLC	ADD	104	204	+96.2%	$5.6K	2025-Q4
ASSETMARK, INC	TRIM	81	58	-28.4%	$1.6K	2025-Q4
FEDERATED HERMES, INC.	ADD	1,072,233	1,635,380	+52.5%	$24.5M	2025-Q3
BlackRock, Inc.	ADD	33,695	50,662	+50.4%	$759.9K	2025-Q3
BANK OF AMERICA CORP /DE/	DOUBLED	55	3,158	+5641.8%	$47.4K	2025-Q3
UBS Group AG	DOUBLED	1	1,560	+155900.0%	$23.4K	2025-Q3

8 unique insiders with 10 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
May 29, 2026	Brun Scott C.	Director	AWARD	18,353	—	—
May 29, 2026	Kornfeld Steven	Director	AWARD	18,353	—	—
May 29, 2026	GRYSKA DAVID W	Director	AWARD	18,353	—	—
May 29, 2026	VINCENT RICHARD G	Director	AWARD	18,353	—	—
May 29, 2026	Kapoor Shivpreet Singh	Director	AWARD	18,353	—	—
May 29, 2026	Doberstein Stephen K	Director	AWARD	18,353	—	—
Apr 1, 2026	Riley Antony A	CHIEF FINANCIAL OFFICER	EXERCISE	375	—	—
Apr 1, 2026	Wagner Paul A.	SEE REMARKS	EXERCISE	1,250	—	—
Apr 1, 2026	Wagner Paul A.	SEE REMARKS	TAX W/H	98	$24.86	$2.4K
Apr 1, 2026	Riley Antony A	CHIEF FINANCIAL OFFICER	TAX W/H	134	$24.86	$3.3K

8 SEC filing reports analyzed. Sentiment: 0 bullish, 5 bearish, 1 mixed, 2 neutral. Avg impact: 5.5/10.

BEARISH EFFECT 6/10

Forte Biosciences' universal shelf registration (File No. 333-296425) became effective on June 10, 2

Jun 11, 2026

BEARISH S-3/A 6/10

Forte Biosciences filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $

Jun 8, 2026

BEARISH S-3 6/10

Forte Biosciences filed a universal shelf registration statement on Form S-3 to offer and sell up to

Jun 5, 2026

NEUTRAL 8-K 3/10

Forte Biosciences filed an 8-K reporting the results of its 2026 annual meeting, where stockholders

Jun 2, 2026

MIXED 8-K 6/10

Forte Biosciences reported Q1 2026 net loss of $1.24/share, wider than the $0.98 consensus miss, wit

May 14, 2026

BEARISH 8-K 7/10

Forte Biosciences reported a net loss per share of $(4.71) for FY 2025, missing consensus estimates,

Apr 21, 2026

NEUTRAL 8-K 5/10

Forte Biosciences announced a $150 million public offering of 5.7 million shares at $26.27 per share

Apr 9, 2026

BEARISH 424B5 5/10

Forte Biosciences is conducting a follow-on public offering of common stock to raise capital, citing

Apr 8, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution (last covering-analyst action Nov 2025): 91% buy across 11 analysts — 3 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.

Analyst Price Targets

Historical data — last covering-analyst action Nov 2025. No current recommendation available.

$63.75 mean target (Nov 2025)

$54.00 Low $75.00 High

Metric	Value
Current Price	$17.56
Target Low	$54.00
Target Mean	$63.75
Target Median	$63.00
Target High	$75.00
# Analysts	4
Recommendation	— (no recent coverage)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-1.01	$-1.11	$-0.89	-5.0%	+4.0%	2↑ 2↓	$0.0B	0.0%	4
Next Q 2026-09-30	$-1.00	$-1.16	$-0.90	-1.5%	+3.4%	3↑ 1↓	$0.0B	0.0%	4
Current FY 2026-12-31	$-4.01	$-4.67	$-3.22	14.9%	—	4↑ 1↓	$0.0B	0.0%	5
Next FY 2027-12-31	$-4.14	$-5.36	$-2.89	-3.3%	—	3↑ 2↓	$0.0B	0.0%	5

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-1.008
7d ago	$-1.050	+0.042
30d ago	$-1.050	+0.042
60d ago	$-0.760	-0.248
90d ago	$-0.830	-0.178

9 analyst firms have rated this stock: 3 upgrades, 5 downgrades, 9 initiations.

Historical Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Nov 25, 2025	Evercore ISI Group	INITIATE	—	Outperform
Nov 17, 2025	Chardan Capital	MAINTAIN	Buy	Buy
Aug 18, 2025	Guggenheim	INITIATE	—	Buy
Aug 15, 2025	Chardan Capital	MAINTAIN	Buy	Buy
Jun 24, 2025	Chardan Capital	MAINTAIN	Buy	Buy
Apr 1, 2025	Chardan Capital	MAINTAIN	Buy	Buy
Jan 21, 2025	TD Cowen	INITIATE	—	Buy
Dec 4, 2024	Chardan Capital	MAINTAIN	Buy	Buy
Nov 15, 2024	Chardan Capital	MAINTAIN	Buy	Buy
Aug 19, 2024	Chardan Capital	MAINTAIN	Buy	Buy
May 30, 2024	Brookline Capital	INITIATE	—	Buy
Apr 8, 2024	Ladenburg Thalmann	UPGRADE	Neutral	Buy
Sep 20, 2021	Chardan Capital	UPGRADE	Sell	Neutral
Sep 3, 2021	Brookline Capital	DOWNGRADE	Buy	Hold
Sep 3, 2021	Chardan Capital	DOWNGRADE	Buy	Sell
Sep 3, 2021	Ladenburg Thalmann	DOWNGRADE	Buy	Neutral
Sep 3, 2021	B. Riley Securities	DOWNGRADE	Buy	Neutral
Sep 3, 2021	Truist Securities	DOWNGRADE	Buy	Hold
May 14, 2021	B. Riley Securities	INITIATE	—	Buy
Mar 26, 2021	Citigroup	INITIATE	—	Buy
Mar 17, 2021	Chardan Capital	MAINTAIN	—	Buy
Sep 24, 2020	Chardan Capital	MAINTAIN	—	Buy
Sep 10, 2020	Chardan Capital	MAINTAIN	—	Buy
Aug 28, 2020	Brookline Capital	INITIATE	—	Buy
Aug 28, 2020	Chardan Capital	UPGRADE	Neutral	Buy
Aug 25, 2020	Truist Securities	INITIATE	—	Buy
Jun 22, 2020	Ladenburg Thalmann	INITIATE	—	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	3	7	1	91%
May 1, 2026	3	8	1	92%
Apr 1, 2026	3	8	1	92%
Mar 1, 2026	3	8	1	92%
Feb 1, 2026	3	8	1	92%
Jan 1, 2026	3	8	1	92%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 3, 2026

FDA

Nalocet

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE AND ACETAMINOPHEN TABLETS Addiction, Abuse, and Misuse Because the use of oxycodone

May 13, 2026

earnings_calendar

FBRX Q1 2026 Earnings Scheduled — 2026-05-13

Mar 26, 2026

earnings_calendar

FBRX Q4 2025 Earnings After Market Close — 2026-03-26